According to Zacks, “Sanofi’s focus on streamlining its business and pursuing business development deals is encouraging. Meanwhile, Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. Products like Toujeo, Aubagio and Lemtrada are likely to do well. Sanofi’s shares outperformed the large-cap pharma group this year. Estimates have increased slightly ahead of the company’s Q4 earnings release. The company has a positive record of earnings surprises in recent quarters. However, Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus, facing intense competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan. Sanofi’s outlook for its Diabetes franchise is also bleak. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent.”
SNY has been the subject of a number of other research reports. Leerink Swann restated an outperform rating on shares of Sanofi in a research report on Tuesday, January 10th. Goldman Sachs Group, Inc. (The) started coverage on Sanofi in a research report on Monday, November 7th. They set a neutral rating for the company. Finally, Morgan Stanley upgraded Sanofi from an equal weight rating to an overweight rating in a research report on Tuesday, November 29th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. Sanofi presently has an average rating of Hold and a consensus price target of $65.67.
Sanofi (NYSE:SNY) opened at 42.57 on Tuesday. The stock has a 50 day moving average price of $40.57 and a 200-day moving average price of $39.74. The stock has a market cap of $109.23 billion, a PE ratio of 21.65 and a beta of 0.98. Sanofi has a 12 month low of $36.81 and a 12 month high of $44.50.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Wednesday, February 8th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.01. Sanofi had a return on equity of 26.37% and a net margin of 13.66%. The business earned $8.88 billion during the quarter, compared to analyst estimates of $9.87 billion. The business’s quarterly revenue was down 4.3% compared to the same quarter last year. On average, analysts expect that Sanofi will post $3.05 EPS for the current year.
Several hedge funds have recently bought and sold shares of the company. CKW Financial Group boosted its position in shares of Sanofi by 21.6% in the third quarter. CKW Financial Group now owns 2,816 shares of the company’s stock valued at $108,000 after buying an additional 500 shares during the last quarter. Signaturefd LLC boosted its stake in Sanofi by 16.4% in the second quarter. Signaturefd LLC now owns 3,480 shares of the company’s stock worth $146,000 after buying an additional 490 shares in the last quarter. FNY Partners Fund LP purchased a new stake in Sanofi during the fourth quarter worth $162,000. JFS Wealth Advisors LLC boosted its stake in Sanofi by 1.9% in the third quarter. JFS Wealth Advisors LLC now owns 4,035 shares of the company’s stock worth $154,000 after buying an additional 74 shares in the last quarter. Finally, Jacobi Capital Management LLC boosted its stake in Sanofi by 31.9% in the third quarter. Jacobi Capital Management LLC now owns 4,271 shares of the company’s stock worth $164,000 after buying an additional 1,034 shares in the last quarter. 9.73% of the stock is currently owned by institutional investors.
Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/sanofi-sny-stock-rating-lowered-by-zacks-investment-research/1657527.html
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.